Additionally, CLDN1 overexpression increases the sensitivity of triple-negative breast cancer cell lines to the chemotherapeutic agents 5-fluorouracil, paclitaxel, and doxorubicin [47]. The gene discussed is CLDN1; the disease is triple-negative breast carcinoma.